|
Name |
Purpurogenolide F
|
| Molecular Formula | C24H26O9 | |
| IUPAC Name* |
21-hydroxy-7,7,15,20,22-pentamethylspiro[2,6,17,19-tetraoxaheptacyclo[11.7.1.11,3.03,12.04,9.015,21.018,22]docosa-4,8-diene-11,2'-oxirane]-10,16-dione
|
|
| SMILES |
CC1OC2OC(=O)C3(C)CC4C5(CO5)C5=CC(=O)OC(C)(C)C5=CC5OC16OC6(C54C)C23O
|
|
| InChI |
InChI=1S/C24H26O9/c1-10-23-24(33-23)20(5)13(8-19(4)16(26)30-17(29-10)22(19,24)27)21(9-28-21)12-7-15(25)32-18(2,3)11(12)6-14(20)31-23/h6-7,10,13-14,17,27H,8-9H2,1-5H3/t10-,13-,14+,17-,19+,20-,21+,22+,23+,24-/m1/s1
|
|
| InChIKey |
DVVDMESWPKTXJA-WZBLSJEASA-N
|
|
| Synonyms |
NA
|
|
| CAS | NA | |
| PubChem CID | NA | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 458.46 | ALogp: | 0.9 |
| HBD: | 1 | HBA: | 9 |
| Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 116.4 | Aromatic Rings: | 8 |
| Heavy Atoms: | 33 | QED Weighted: | 0.424 |
| Caco-2 Permeability: | -5.249 | MDCK Permeability: | 0.00001440 |
| Pgp-inhibitor: | 0.993 | Pgp-substrate: | 0.05 |
| Human Intestinal Absorption (HIA): | 0.09 | 20% Bioavailability (F20%): | 0.954 |
| 30% Bioavailability (F30%): | 0.909 |
| Blood-Brain-Barrier Penetration (BBB): | 0.917 | Plasma Protein Binding (PPB): | 78.18% |
| Volume Distribution (VD): | 1.813 | Fu: | 19.46% |
| CYP1A2-inhibitor: | 0.002 | CYP1A2-substrate: | 0.988 |
| CYP2C19-inhibitor: | 0.022 | CYP2C19-substrate: | 0.83 |
| CYP2C9-inhibitor: | 0.044 | CYP2C9-substrate: | 0.006 |
| CYP2D6-inhibitor: | 0.002 | CYP2D6-substrate: | 0.091 |
| CYP3A4-inhibitor: | 0.161 | CYP3A4-substrate: | 0.934 |
| Clearance (CL): | 2.208 | Half-life (T1/2): | 0.044 |
| hERG Blockers: | 0.002 | Human Hepatotoxicity (H-HT): | 0.211 |
| Drug-inuced Liver Injury (DILI): | 0.958 | AMES Toxicity: | 0.972 |
| Rat Oral Acute Toxicity: | 0.939 | Maximum Recommended Daily Dose: | 0.17 |
| Skin Sensitization: | 0.046 | Carcinogencity: | 0.957 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.045 |
| Respiratory Toxicity: | 0.904 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003843 | ![]() |
0.624 | D06IIB | ![]() |
0.234 | ||
| ENC002931 | ![]() |
0.455 | D0KR9U | ![]() |
0.234 | ||
| ENC003927 | ![]() |
0.442 | D02QJH | ![]() |
0.231 | ||
| ENC005628 | ![]() |
0.380 | D02JNM | ![]() |
0.229 | ||
| ENC002849 | ![]() |
0.309 | D03ZZK | ![]() |
0.227 | ||
| ENC004709 | ![]() |
0.304 | D0Y2YP | ![]() |
0.217 | ||
| ENC002987 | ![]() |
0.301 | D0G6AB | ![]() |
0.216 | ||
| ENC005315 | ![]() |
0.297 | D0P0HT | ![]() |
0.209 | ||
| ENC002851 | ![]() |
0.296 | D0Q4SD | ![]() |
0.208 | ||
| ENC003408 | ![]() |
0.294 | D0D2TN | ![]() |
0.207 | ||